Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Polyethylene Terephthalate
100%
Positron Emission Tomography-Computed Tomography
95%
Tomotherapy
80%
Clinical Trial
71%
Breast Cancer
62%
Rectum Cancer
61%
Neoplasm
60%
Fluorodeoxyglucose F 18
59%
positron emission tomographic scan
58%
Glioblastoma
58%
Radiation Therapy
57%
Overall Survival
57%
Ganglioglioma
55%
Non Small Cell Lung Cancer
55%
Melanoma
46%
Nanobody
46%
Single-Photon Emission Computed Tomography
45%
Ipilimumab
42%
Adverse Event
39%
Phase II Trials
39%
Chemotherapy
39%
Iodine 123
37%
Gallium 68
36%
Temozolomide
36%
Nivolumab
30%
Sunitinib
30%
Progression Free Survival
30%
Fluorodeoxyglucose
29%
Injection
28%
Monoclonal Antibody
28%
Fluorine-18
27%
Radioactive Tracer
27%
Magnetic Resonance Imaging
27%
Breast Carcinoma
26%
Colorectal Carcinoma
26%
Computer Assisted Tomography
26%
Head and Neck Cancer
26%
Diseases
26%
Gamma Urogastrone
25%
Epidermal Growth Factor Receptor 2
24%
Axitinib
24%
Heart Muscle Perfusion
24%
Photon Emission Tomography
24%
Biodistribution
24%
Low Drug Dose
23%
Preoperative Radiotherapy
20%
Pulmonary Embolism
20%
Lomustine
19%
CTLA-4
19%
Liver Metastasis
19%
Pharmacology, Toxicology and Pharmaceutical Science
Polyethylene Terephthalate
66%
Nanobody
52%
Neoplasm
45%
Melanoma
40%
Clinical Trial
38%
Gallium 68
35%
Adverse Event
30%
Tracer
26%
Breast Carcinoma
26%
Biodistribution
23%
Breast Cancer
19%
Ipilimumab
18%
Mannose Receptor
18%
Overall Survival
18%
Fluorodeoxyglucose F 18
16%
Pembrolizumab
14%
Diseases
14%
Gamma Urogastrone
14%
Skin Toxicity
14%
Indium 111
14%
Phase II Trials
14%
Dosimetry
13%
Chemoradiation Therapy
13%
Radioactive Iodine
13%
Glioblastoma
12%
Non Small Cell Lung Cancer
12%
Sunitinib
12%
Head and Neck Cancer
12%
Metastatic Melanoma
12%
Epidermal Growth Factor Receptor 2
12%
Congestive Heart Failure
12%
Solid Malignant Neoplasm
12%
Dabrafenib
12%
Trametinib
12%
Sarcoidosis
12%
Malignant Neoplasm
12%
Remission
10%
Heart Infarction
10%
Methoxy Isobutyl Isonitrile Technetium Tc 99m
9%
Human Study
8%
Iodine-131
8%
Mitogen Activated Protein Kinase Kinase Inhibitor
8%
Progression Free Survival
8%
Normal Human
8%
Antitumor Activity
7%
Brain Metastasis
7%
Iodine
7%
Radioisotope
7%
Monotherapy
7%
Fluorodeoxyglucose
7%
Immunology and Microbiology
Positron Emission Tomography-Computed Tomography
71%
Overall Survival
48%
Metabolic Tumor Volume
46%
Pembrolizumab
45%
Single-Domain Antibody
30%
Progression Free Survival
24%
positron emission tomographic scan
24%
Gamma Urogastrone
19%
Monoclonal Antibody
16%
Magnetic Resonance Imaging
15%
Axitinib
12%
Sunitinib
12%
Nivolumab
12%
Immunotherapy
11%
Tumor Volume
10%
Perfusion
10%
Ipilimumab
9%
Kinase
9%
Phosphotransferase
9%
Lymph Node
8%
Lactic Acid
8%
Tyrosine
8%
Lymphocyte Count
7%
Lung
7%
Glycolysis
6%
Single Photon Emission Computed Tomography
6%
Macrophage
6%
Mannose Receptor
6%
Trametinib
6%
Tincture of Iodine
6%
Immune Response
6%
Gene Expression Assay
6%
Iodine
6%
Sarcoidosis
6%
Adolescence
6%
Graves' Disease
6%
CTLA-4
6%
Low Drug Dose
6%
Neck
6%
Avelumab
6%
Wild Type
6%
Programmed Death 1 Ligand 1
6%
Pseudoprogression
6%
Regorafenib
6%
C-Reactive Protein
5%
Pretreatment
5%
Evolution
5%
Blood Plasma
5%
